What is Magellan Diagnostics?
Magellan Diagnostics is a prominent medical device company headquartered near Boston, Massachusetts. The firm specializes in providing advanced point-of-care systems, clinical laboratory instruments, and analytical laboratory services, with a primary focus on lead testing. Dedicated to raising awareness about the severe and permanent health consequences of lead exposure, Magellan Diagnostics offers reliable products designed for the rapid identification of affected individuals, serving families, clinicians, policymakers, payers, and communities.
How much funding has Magellan Diagnostics raised?
Magellan Diagnostics has raised a total of $50M across 1 funding round:
Private Equity
$50M
Private Equity (2006): $50M with participation from Abingworth, Tekla Capital Management, and Ampersand Capital Partners
Key Investors in Magellan Diagnostics
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that supports cutting-edge science by providing capital and expertise to build world-class companies. Their therapeutic-focused investments span seed, early-stage, development stage, and clinical co-development.
Tekla Capital Management
Aberdeen Investments is a global specialist asset manager offering investment solutions across various asset classes for individual, financial advisor, and institutional clients. They emphasize sustainable investing and innovative strategies to help clients meet their objectives.
Ampersand Capital Partners
Ampersand Capital Partners is a middle market private equity firm focused on growth-oriented investments in the healthcare sector. With extensive experience, they leverage their blend of private equity and operating expertise to build value and drive performance in their portfolio companies.
What's next for Magellan Diagnostics?
The substantial enterprise-level funding Magellan Diagnostics has attracted, particularly the recent major strategic investment, signals a phase of accelerated scaling and market expansion. This capital infusion is expected to fuel further innovation in their diagnostic technologies and broaden their reach in addressing the critical public health issue of lead exposure. The company is well-positioned to enhance its product development and solidify its market leadership.
See full Magellan Diagnostics company page
